Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

OBJECTIVE: This analysis compared the efficacy and safety of the sodium-glucose cotransporter-2 (SGLT2) inhibitor, dapagliflozin, and the dipeptidyl peptidase-4 (DPP4) inhibitor, saxagliptin, both added on to metformin. MATERIALS AND METHODS: This was a post-hoc analysis from a double-blind, randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Mathieu, Chantal, Chen, Hungta, Garcia-Sanchez, Ricardo, Saraiva, Gabriela Luporini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118728/
https://www.ncbi.nlm.nih.gov/pubmed/30304106
http://dx.doi.org/10.20945/2359-3997000000056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118728/
https://www.ncbi.nlm.nih.gov/pubmed/30304106
http://dx.doi.org/10.20945/2359-3997000000056

Ejemplares similares